"Prior, underpowered studies suggested that there was no downside to intermittent therapy, which clearly provides less toxicity," he said at the press briefing. "This study for the first time indicates that there is a price to pay."
Lepor agreed that, "on the basis of this study, intermittent androgen [hormonal] deprivation therapy should no longer be recommended for those men with minimal disease spread."
Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.
There's more on treatments for prostate cancer at the American Cancer Society.
Copyright © 2012 HealthDay. All rights reserved.